^
    22h
    Asciminib With or Without Sildenafil for Brain Tumors (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Washington University School of Medicine | Trial completion date: Nov 2027 --> Mar 2028 | Initiation date: Apr 2026 --> Aug 2026 | Trial primary completion date: Oct 2027 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Scemblix (asciminib) • sildenafil
    2d
    Laparoscopic excision of proximal ileal GIST presenting with massive upper GI bleeding: a case report. (PubMed, Int J Surg Case Rep)
    Adjuvant tyrosine kinase inhibitors, such as imatinib, are reserved for high-risk lesions or unresectable tumors. This case highlights the importance of considering GIST as a differential diagnosis in obscure upper GI bleeding. It also demonstrates that laparoscopic resection is a safe and effective treatment option for ileal GISTs, even in the context of acute bleeding.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • ANO1 (Anoctamin 1)
    |
    KIT positive
    |
    imatinib
    2d
    Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images. (PubMed, Cancer Res)
    For therapeutic categories, performance reached 0.84 for avapritinib sensitivity and 0.81 for imatinib sensitivity. Prognostic performance was comparable to pathology-based scores, with highest discrimination in the overall cohort and in patients without adjuvant therapy. DL applied to WSIs enables prediction of molecular alterations, treatment sensitivity, and RFS in GIST, performing comparably to established risk scores across international cohorts, providing a baseline for future multimodal predictors.
    Journal
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    KIT mutation • PDGFRA D842V • PDGFRA mutation
    |
    imatinib • Ayvakit (avapritinib)
    5d
    Unmasking the "targetless" illusion: branched clonal evolution of TERT and KIT in acral melanoma revealed by sequential multi-site biopsies- a case report. (PubMed, Front Immunol)
    The study also showed the inherent resistance of the KIT p.Ala829Pro mutation to imatinib, explaining the failure of subsequent treatment. This study highlights the significant spatial and temporal heterogeneity of acral melanoma and underscores the critical importance of serial biopsies in accurately capturing clonal dynamics and guiding precision oncology therapy.
    Journal • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • TERT (Telomerase Reverse Transcriptase)
    |
    imatinib
    7d
    PRKCA and ABCB1 dual-enriched exosomes are key drivers of drug resistance in chronic myeloid leukemia. (PubMed, Drug Resist Updat)
    PRKCA and ABCB1 dual-enriched exosomes are key drivers of drug resistance in CML patients, and exosomal PRKCA and ABCB1 may serve as diagnostic and therapeutic targets for CML.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • FOXA1 (Forkhead Box A1) • ETS1 (ETS Proto-Oncogene 1) • PRKCA (Protein Kinase C Alpha) • MARCKS (Myristoylated Alanine Rich Protein Kinase C Substrate)
    |
    imatinib • doxorubicin hydrochloride
    7d
    PONTHIAC: Safety and efficacy of treatment combination with ponatinib and asciminib in chronic myeloid leukemia patients resistant to ponatinib and/or asciminib (2025-521126-15-00)
    P1/2, N=30, Not yet recruiting, Grupo Espanol De Leucemia Mieloide Cronica (GELMC)
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Iclusig (ponatinib) • Scemblix (asciminib)
    9d
    Primary Multifocal Hepatic Gastrointestinal Stromal Tumor Mimicking Metastatic Disease: A Diagnostic Challenge With PET-CT and Histopathological Correlation. (PubMed, Cureus)
    On follow-up PET-CT scan after imatinib therapy, the patient showed a complete/near complete metabolic response. This report expands the imaging spectrum of PHGIST and emphasizes the importance of radiologic-pathologic correlation in distinguishing this rare lesion from metastatic liver disease.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    imatinib
    12d
    To Explore the Optimal Therapeutic Window for Imatinib in the Adjuvant Treatment of Intermediate and High-risk Gastrointestinal Stromal Tumors (clinicaltrials.gov)
    P=N/A, N=328, Completed, First Affiliated Hospital, Sun Yat-Sen University
    New trial
    |
    imatinib
    12d
    Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML (clinicaltrials.gov)
    P3, N=8, Terminated, Sarit Assouline | N=164 --> 8 | Trial completion date: Dec 2025 --> Jul 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Jul 2025; Insufficient patient accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    imatinib • Scemblix (asciminib)
    12d
    Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis (clinicaltrials.gov)
    P2, N=21, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    paclitaxel • nilotinib